title: A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
abstract: To assess the efficacy and safety of a primary immunosuppressive regimen with tacrolimus (Tac) and low-dose mycophenolate mofetil (MMF) without steroids and to determine the exposure to mycophenolic acid (MPA) in the early postoperative period, we performed a single-center, randomized 1:1, open-label, controlled study planned to be 60 liver transplantation patients randomized into 2 groups: group A, tacrolimus + MMF (750 mg orally twice a day); and group B, tacrolimus + MMF (750 mg orally twice a day) + steroids. After an interim analysis by the ethical committee patient enrollment was stopped. Data from 30 patients (12 in group A and 18 in group B with a mean follow-up period of 31 +/- 7 months) showed a patient survival rate of 91.7% in group A and 100% in group B and a graft survival rate of 91.7% and 88.9%, respectively. Nine patients (75%) in group A suffered an acute rejection episode, whereas in group B only 3 patients (16.7%) showed acute rejection (P = .002). All rejection episodes occurred in both groups at 1 week after transplantation. The difference in histological grading was statistically significant (P = .021). The toxicity profiles were similar in both groups. A primary immunosuppressive regimen based on Tac and low-dose MMF without steroids is safe but unable to prevent acute rejection at 1 week after transplantation even if early acute rejection does not affect the outcome in terms of morbidity and graft or patient survival.
authors.affiliation: Centro Trapianti Fegato e Polmone, IRCCS Ospedale Maggiore, Milano, Italy. paolo.reggiani@libero.it
authors.forename: P
authors.initials: P
authors.lastname: Reggiani
authors.forename: M
authors.initials: M
authors.lastname: Arru
authors.forename: M
authors.initials: M
authors.lastname: Regazzi
authors.forename: S
authors.initials: S
authors.lastname: Gatti
authors.forename: M D
authors.initials: MD
authors.lastname: Molinaro
authors.forename: L
authors.initials: L
authors.lastname: Caccamo
authors.forename: U
authors.initials: U
authors.lastname: Maggi
authors.forename: E
authors.initials: E
authors.lastname: Melada
authors.forename: G
authors.initials: G
authors.lastname: Paone
authors.forename: G
authors.initials: G
authors.lastname: Rossi
mesh_terms: D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D019540:Area Under Curve; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D011184:Postoperative Period; D016019:Survival Analysis; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus